Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

October 31, 2003

Conditions
Schizophrenia
Interventions
DRUG

R209130

Trial Locations (29)

10304

Bayley Seton Campus-Psychiatric Research Division, Staten Island

10305

Behavioral Medical Research of Staten Island, P.C., Staten Island

11559

Neurobehavioral Research, Lawrence

14760

CNS Research Institute, Clementon

Global Research & Consulting, Olean

20016

Psychiatric Institute of Washington, Washington D.C.

30340

Med Psych Specialists, LLC, Atlanta

33016

Berma Research Group, Hialeah

33064

Quantum Laboratories, Pompano Beach

33161

Segal Institute for Clinical Research, North Miami

35209

Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham

37212

Vanderbilt University Medical Center, Nashville

39216

University of Mississippi Medical Center-Dept. of Psychiatry, Jackson

44122

NorthCoast Clinical Trials, Beachwood

53295

Milwaukee VA Medical Center, Milwaukee

60181

Midwest Center for Neurobehavioral Medicine, Oakbrook Terrace

60194

Alexian Brothers Behavioral Health Hospital, Hoffman Estates

71101

Shreveport

73103

IPS Research, Oklahoma City

75062

University Hills Clinical Research, Irving

77057

MedLabs Research of Houston, Houston

78756

Community Clinical Research, Austin

80262

University of Colorado, Denver

90503

Research Strategies, Torrance

90703

IPR, Cerritos

91910

Synergy Clinical Research, Chula Vista

91942

Optimum Health Services, La Mesa

92705

Clinical Innovations, Santa Ana

95823

Sierra Vista Hospital, Sacramento

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00063297 - Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter